DK1677833T3 - Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom - Google Patents
Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdomInfo
- Publication number
- DK1677833T3 DK1677833T3 DK04791259.7T DK04791259T DK1677833T3 DK 1677833 T3 DK1677833 T3 DK 1677833T3 DK 04791259 T DK04791259 T DK 04791259T DK 1677833 T3 DK1677833 T3 DK 1677833T3
- Authority
- DK
- Denmark
- Prior art keywords
- neurturin
- gene therapy
- vivo gene
- parkinson
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301543 | 2003-10-20 | ||
US51291803P | 2003-10-22 | 2003-10-22 | |
PCT/EP2004/052586 WO2005039643A2 (en) | 2003-10-20 | 2004-10-20 | In vivo gene therapy of parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1677833T3 true DK1677833T3 (da) | 2010-05-17 |
Family
ID=34524307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04791259.7T DK1677833T3 (da) | 2003-10-20 | 2004-10-20 | Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP1677833B1 (da) |
JP (1) | JP2007509109A (da) |
KR (1) | KR20060095568A (da) |
AT (1) | ATE460183T1 (da) |
AU (1) | AU2004283053A1 (da) |
BR (1) | BRPI0415563A (da) |
CA (1) | CA2543189A1 (da) |
DE (1) | DE602004025959D1 (da) |
DK (1) | DK1677833T3 (da) |
ES (1) | ES2342397T3 (da) |
MX (1) | MXPA06004329A (da) |
NZ (1) | NZ547185A (da) |
RU (1) | RU2006117304A (da) |
WO (1) | WO2005039643A2 (da) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
NZ544263A (en) | 2003-06-10 | 2009-04-30 | Nsgene As | Improved secretion of neublastin |
US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
KR101241551B1 (ko) | 2004-08-19 | 2013-03-11 | 바이오겐 아이덱 엠에이 인코포레이티드 | 전환 성장 인자 베타 패밀리 단백질의 리폴딩 |
CA2627543A1 (en) * | 2005-10-28 | 2007-05-03 | Ns Gene A/S | Implantable biocompatible immttnoisolatory vehicle for delivery of gdnf |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US9375440B2 (en) | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
EP2142205B1 (en) | 2007-05-01 | 2014-04-02 | Biogen Idec MA Inc. | Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow |
MX2010004899A (es) * | 2007-11-05 | 2010-09-07 | Develogen Ag | Conjugados de neurturina novedosos para uso farmaceutico. |
ES2762864T3 (es) * | 2008-06-18 | 2020-05-26 | Oxford Biomedica Ltd | Purificación de virus |
EP2493918A4 (en) * | 2009-10-30 | 2013-04-10 | Ntf Therapeutics Inc | IMPROVED NEURTURINE MOLECULES |
BR112013013255A2 (pt) * | 2010-12-02 | 2020-08-25 | Neurotech Usa, Inc. | linhagens celulares que secretam anticorpos-esqueletos antiangiogênicos e receptores solúveis e usos das mesmas |
DK2661494T3 (da) * | 2011-01-07 | 2019-09-02 | Applied Genetic Tech Corporation | Promotorer, ekspressionskassetter og vektorer til anvendelse ved behandling af achromatopsi og andre sygdomme |
IN2015KN00074A (da) * | 2012-07-06 | 2015-07-31 | Univ Iowa Res Found | |
HUE046292T2 (hu) | 2012-08-13 | 2020-02-28 | Univ Rockefeller | Melanóma kezelése és diagnosztizálása |
CN104918659B (zh) | 2012-10-31 | 2019-03-19 | 洛克菲勒大学 | 结肠癌的治疗和诊断 |
CN103981147B (zh) | 2013-02-08 | 2017-11-10 | 中国科学院上海生命科学研究院 | 一种新的制备肝实质细胞的方法 |
US10967073B2 (en) | 2015-05-07 | 2021-04-06 | The Mclean Hospital Corporation | Glucocerebrosidase gene therapy for Parkinson's disease |
US10016514B2 (en) | 2015-05-15 | 2018-07-10 | New Hope Research Foundation | Polynucleotides, vectors and methods for insertion and expression of transgenes |
WO2017081082A2 (en) * | 2015-11-09 | 2017-05-18 | Curevac Ag | Optimized nucleic acid molecules |
US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
TW202136188A (zh) | 2019-12-13 | 2021-10-01 | 美商睿治尼斯公司 | 金屬鹽及其用途 |
WO2024091824A1 (en) | 2022-10-26 | 2024-05-02 | Ada Forsyth Institute, Inc. | Differentiation and reprogramming of chondrocyte |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0228458B2 (en) | 1985-07-05 | 1997-10-22 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
EP0378576B1 (en) | 1987-09-11 | 1995-01-18 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
US5487739A (en) | 1987-11-17 | 1996-01-30 | Brown University Research Foundation | Implantable therapy systems and methods |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US5156844A (en) | 1987-11-17 | 1992-10-20 | Brown University Research Foundation | Neurological therapy system |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
JP4215273B2 (ja) | 1991-04-25 | 2009-01-28 | ブラウン ユニヴァーシティ リサーチ ファンデーション | 選択された治療物質放出用の移植可能で生体適合性の免疫遮断性ビークル |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
AU688776B2 (en) | 1993-06-23 | 1998-03-19 | Brown University Research Foundation | Method and apparatus for sealing implantable, membrane encapsulation devices |
AU7568094A (en) | 1993-08-12 | 1995-03-14 | Cytotherapeutics, Inc. | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
AU710504B2 (en) | 1994-03-15 | 1999-09-23 | Brown University Research Foundation | Polymeric gene delivery system |
US20020031493A1 (en) | 1994-03-25 | 2002-03-14 | Rhone-Poulenc Rorer S.A. | Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf) |
ATE386131T1 (de) | 1994-04-13 | 2008-03-15 | Univ Rockefeller | Aav-vermittelte überbringung von dna in zellen des nervensystems |
US5550050A (en) | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
US5656465A (en) | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
US5677158A (en) | 1995-06-07 | 1997-10-14 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
US5739307A (en) | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
US6184200B1 (en) | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
US5904144A (en) | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
US6027721A (en) | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
US6054142A (en) | 1996-08-01 | 2000-04-25 | Cyto Therapeutics, Inc. | Biocompatible devices with foam scaffolds |
SI1005358T1 (en) * | 1997-07-30 | 2003-06-30 | Amgen Inc. | Use of a neurturin protein product for preventing and treating hearing loss |
US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
US6303136B1 (en) | 1998-04-13 | 2001-10-16 | Neurotech S.A. | Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane |
US6451306B1 (en) | 1998-04-15 | 2002-09-17 | The Regents Of The University Of California | Methods for therapy of neurodegenerative disease of the brain |
EP1080202B1 (en) | 1998-05-27 | 2006-01-25 | Avigen, Inc. | Convection-enhanced delivery of aav vectors encoding aadc |
US20020055467A1 (en) | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
US6361741B1 (en) | 1999-02-01 | 2002-03-26 | Alcoa Inc. | Brazeable 6XXX alloy with B-rated or better machinability |
US6361771B1 (en) | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
EP1301214A2 (en) | 2000-05-26 | 2003-04-16 | Chiron Corporation | Methods of transducing neural cells using lentivirus vectors |
US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
US6800281B2 (en) | 2000-11-09 | 2004-10-05 | Oxford Biomedica (Uk) Limited | Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases |
US20030050273A1 (en) | 2001-08-29 | 2003-03-13 | Keiya Ozawa | Compositions and methods for treating neurodegenerative diseases |
-
2004
- 2004-10-20 MX MXPA06004329A patent/MXPA06004329A/es not_active Application Discontinuation
- 2004-10-20 DE DE602004025959T patent/DE602004025959D1/de active Active
- 2004-10-20 DK DK04791259.7T patent/DK1677833T3/da active
- 2004-10-20 BR BRPI0415563-7A patent/BRPI0415563A/pt not_active Application Discontinuation
- 2004-10-20 EP EP04791259A patent/EP1677833B1/en not_active Not-in-force
- 2004-10-20 ES ES04791259T patent/ES2342397T3/es active Active
- 2004-10-20 AU AU2004283053A patent/AU2004283053A1/en not_active Abandoned
- 2004-10-20 WO PCT/EP2004/052586 patent/WO2005039643A2/en active Application Filing
- 2004-10-20 CA CA002543189A patent/CA2543189A1/en not_active Abandoned
- 2004-10-20 AT AT04791259T patent/ATE460183T1/de not_active IP Right Cessation
- 2004-10-20 KR KR1020067007666A patent/KR20060095568A/ko not_active Application Discontinuation
- 2004-10-20 JP JP2006536086A patent/JP2007509109A/ja not_active Withdrawn
- 2004-10-20 NZ NZ547185A patent/NZ547185A/en not_active IP Right Cessation
- 2004-10-20 EP EP10155955A patent/EP2210617A1/en not_active Withdrawn
- 2004-10-20 RU RU2006117304/15A patent/RU2006117304A/ru unknown
Also Published As
Publication number | Publication date |
---|---|
EP1677833A2 (en) | 2006-07-12 |
DE602004025959D1 (de) | 2010-04-22 |
EP2210617A1 (en) | 2010-07-28 |
RU2006117304A (ru) | 2007-12-10 |
AU2004283053A1 (en) | 2005-05-06 |
WO2005039643A3 (en) | 2005-11-17 |
ATE460183T1 (de) | 2010-03-15 |
WO2005039643A2 (en) | 2005-05-06 |
CA2543189A1 (en) | 2005-05-06 |
ES2342397T3 (es) | 2010-07-06 |
NZ547185A (en) | 2009-03-31 |
MXPA06004329A (es) | 2006-06-05 |
JP2007509109A (ja) | 2007-04-12 |
KR20060095568A (ko) | 2006-08-31 |
EP1677833B1 (en) | 2010-03-10 |
BRPI0415563A (pt) | 2007-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1677833T3 (da) | Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom | |
EA200800368A1 (ru) | Гликозилированный il-7, получение и применение | |
WO2005077333A3 (en) | Gel-based delivery of recombinant adeno-associated virus vectors | |
WO2003104270A3 (en) | GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES | |
WO2004022716A3 (en) | Recombinatant mutants of rhabdovirus and methods of use thereof | |
BE2014C077I2 (da) | ||
WO2003032994A3 (de) | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren | |
EP1315965A4 (en) | METHODS AND COMPOSITIONS FOR IN VITRO TARGETING | |
EP1140971A4 (en) | ANTISENS MODULATION OF NEW ANTI-APOPTOTIC BCL-2-LIKE PROTEINS | |
BR0207110A (pt) | Pró-peptìdeos de gdf modificados e estabilizados e usos dos mesmos | |
AU9063801A (en) | Methods and compositions for diseases associated with amyloidosis | |
WO1998049300A3 (en) | Truncated vegf-related proteins | |
CY1107351T1 (el) | Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης | |
DK1745069T3 (da) | Terapeutisk anvendelse af vækstfaktoren NSG33 | |
ATE457359T1 (de) | Auf lps-reagierendes chs1/beige-ähnliches anker- gen und therapeutische anwendungen davon | |
AR037038A1 (es) | Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto | |
DE60328673D1 (de) | Optimierung von transgenexpression in säugetierzellen | |
EP1209226A3 (en) | Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70) | |
HUP0500637A2 (hu) | Neublasztin polimer konjugátumai és alkalmazási eljárásai | |
ATE365807T1 (de) | Hepatitis b virus vektoren für gentherapie | |
ATE529438T1 (de) | Dna-sequenz und rekombinante herstellung des graspollen-allergens lol p 4 | |
ATE371737T1 (de) | Proteaseresistente flint-analoge | |
WO2004074312A3 (en) | Tryptophyllin peptides and uses thereof | |
ATE394420T1 (de) | Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür | |
WO2001083688A3 (fr) | Nouveau polypeptide, sous-unite humaine 13 phosphatidylinositol-4-phosphate-5-kinase ii beta, et polynucleotide codant pour ce polypeptide |